Anjali Tiku Named to CorVista Health’s Medical Advisory Board

CorVista Health Inc. has expanded its Medical Advisory Board by appointing Anjali Tiku Owens, M.D., to the governing body.
 
Owens is an associate professor of Medicine in the Division of Cardiology, Section of Heart Failure and Transplantation at the Perelman School of Medicine of the University of Pennsylvania. She is the founding director of the Penn Familial Cardiomyopathy Program, director of the Hypertrophic Cardiomyopathy clinic, and was appointed medical director of the Penn Center for Inherited Cardiovascular Disease in 2015. She has a special interest in novel therapies for genetic cardiomyopathy.
 
“As we near commercialization of our first indication of the CorVista System for Coronary Artery Disease (CAD), it is essential we continue to bring cardiovascular experts onboard our Medical Advisory Board. We are thrilled to welcome Dr. Anjali Tiku Owens to our board,” CorVista Health President/CEO Don Crawford stated. “Dr. Tiku Owens’ experience and expertise in cardiology, particularly in genetic cardiomyopathy and novel therapies, will be invaluable as we work to revolutionize cardiovascular care.”
 
The U.S. Food and Drug Administration cleared the CorVista System with CAD Add-On last fall. The CorVista System is a non-invasive point-of-care solution intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise. Within minutes of the test, the CorVista Analysis is available in a secure web portal to aid physicians in rapidly diagnosing and treating patients with suspected cardiovascular disease, answering important clinical questions to guide better treatment decisions. Additional CorVista System Add-Ons for pulmonary hypertension and LV filling pressure are currently investigational devices limited by federal or United States law to investigational use and are not available for commercial distribution. CorVista System is developed and manufactured by Analytics 4 Life Inc., and licensed exclusively to CorVista Health.
 
“I am honored to join CorVista Health’s Medical Advisory Board and contribute to the advancement of cardiovascular care,” Owens said. “The CorVista System holds promise in transforming how we diagnose and treat cardiovascular diseases. I look forward to collaborating with CorVista and the Medical Advisory Board to make a meaningful impact on patient outcomes.”
 
Bethesda, Md.-based CorVista Health Inc. applies machine learning to deliver cardiac disease detection algorithms that enhance the CorVista System platform over time.